The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

Disclosed herein, in certain embodiments, are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the proteins are regulated by NRF2. In some instances, also described herein are protein-binding domains that interact with a probe and/or a ligand described herein, in which the proteins are regulated by NRF2.

A marker for health assessment, and an application thereof, relating to the field of medical test. An application of a marker identification reagent in preparation of a reagent for measuring the health of a mammal, comprising: (1) measuring a marker in a test sample, wherein the marker is the level of 8-oxoGsn; and (2) comparing the marker with a reference, wherein the difference between the marker and the reference is used for assessing the health condition of the subject. According to the invention, comprehensive health condition assessment is performed on a subject by means of a simple clinical examination method, and the health condition and health laws of people can be obtained timely and quickly; compared with conventional medical test methods, the invention has remarkable advantages in detection and early warning of sub-health, disease treatment effect monitoring, and psychological emotional state detection in the field of health service management.

Disclosed herein are embodiments of donor compounds that can be used to produce H.sub.2S from COS or CS.sub.2 released from the donor compounds. In some embodiments, the donor compounds can indirectly produce H.sub.2S after being exposed to a reactive component in a triggering event. In other embodiments, the donor compounds can indirectly regenerate H.sub.2S after reacting with an H.sub.2S analyte. The donor compounds disclosed herein can be used for analytical techniques, disease diagnostics, and/or therapeutic applications. Methods of making and using the donor compounds also are provided herein.

Compositions and methods for determining the level of thiol and disulfide containing molecules in a sample are provided. The compositions and methods can be used to determine the level of oxidative stress in a subject with or without antioxidant treatment. Also provided are biomarkers of oxidative stress.

The invention relates to diagnostic methods for assessing the need of a subject for treatment with an anti-oxidant, or alternatively, for determining the utilization efficiency and ultimate effectiveness of anti-oxidant therapy in subjects having been treated with antioxidants. More specifically, the methods of the present invention are particularly useful in prophylactic assessment of individuals at risk for developing diseases or conditions in which oxidative stress plays a role, such that an appropriate therapeutic regimen can be prescribed for that individual, thus leading to alternative therapies and/or life style changes. The invention further relates to methods for assessing the need for, the utilization efficiency and the effectiveness of therapy in subjects having received therapy with specific antioxidant and immune enhancing formulations. Kits are also provided for measuring the levels of markers of oxidative stress and immune cell numbers.

The present invention relates to a fluorescence sensor capable of real-time imaging for measuring a cellular thiol level. The present invention reveals that the fluorescence intensity of the fluorescent real-time SH group-tracer (FreSH-Tracer) of the present invention increases or decreases continuously, ratiometrically or reversibly depending on the thiol level in living cells, and thus can be usefully used as a biosensor which is remarkably susceptible to quantitative or qualitative real-time detection of the cellular thiol level in living cells.

A biosensor, including a modified gold electrode and a macrophage RAW264.7 immobilized on the modified gold electrode. The disclosure also provides a method of preparing the biosensor and a method of using the same for evaluation of antioxidant capacity of substances.

The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated. The invention also relates to kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) having relevance for the symptoms discussed herein.